Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 1, 2021CNS DrugsOpen Access

Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox–Gastaut Syndrome

View Full Paper
Ask AI
Bookmark
Share

Authors

SLSimona LattanziMarche Polytechnic UniversityETEugen TrinkaParacelsus Medical UniversityPSPasquale StrianoGreat Ormond Street Hospital

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Lattanzi et al. (2021) studied this question.

synapsesocial.com/papers/6a73b539377577bf844ca12ehttps://doi.org/10.1007/s40263-021-00807-y
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Practical use of pharmaceutically purified oral cannabidiol in Dravet syndrome and Lennox-Gastaut syndrome2020 · 33 citations
  2. 2Characteristics of clinical trials in rare vs. common diseases: A register-based Latvian study2018 · 32 citations
  3. 3Making the switch: From case studies to N-of-1 trials2019 · 50 citations
  4. 4Long‐term safety and treatment effects of cannabidiol in children and adults with treatment‐resistant epilepsies: Expanded access program results2018 · 206 citations
  5. 5Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study2018 · 171 citations